Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of the differential expression between carcinoma and normal mucosa showed that SMAD3 rs12708491 and rs2414937, NFκB1 rs230510 and rs3821958, and RUNX3 rs6672420 were associated with several miRNAs for colorectal carcinoma.
|
28061442 |
2017 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The RUNX3 rs2236852 AA genotype and A allele showed association with CRC (OR = 0.39, 95%CI = 0.21-0.73, P < 0.01; OR = 0.65, 95%CI = 0.49-0.87, P < 0.01, respectively), while the rs6672420, rs11249206, and rs760805 polymorphisms did not show significant association with CRC.
|
26634516 |
2015 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer.
|
30692634 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of the 62 CRC tissue samples, 20 (32.3%) presented hypermethylated RUNX3 promoters.
|
29333422 |
2018 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CIMP status was also determined by methylation-specific quantitative PCR method (MethyLight) using eight CIMP markers (MLH1, NEUROG1, CRABP1, CACNA1G, CDKN2A (p16), IGF2, SOCS1, and RUNX3) in 216 MSI-H CRCs.
|
25973084 |
2015 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings supported CNRIP1 and RUNX3 as potential DNA methylation biomarkers for CRC diagnosis and treatment, and our LC-MS/MS approach exhibited great advantages in the identification of regional DNA methylation biomarkers.
|
28940471 |
2017 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated genetic variation in RUNX1 (40 tagSNPs), RUNX2 (19 tagSNPs), RUNX3 (9 tagSNPs), MAPK1 (6 tagSNPs), eIF4E (3 tagSNPs), eIF4EBP2 (2 tagSNP) and eIF4EBP3 (2 tagSNPs) to determine associations with colorectal cancer (CRC).
|
21088106 |
2011 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous study showed that RUNX3 inhibits invasiveness by preventing vascular endothelial growth factor secretion and suppressed endothelial cell growth and tube formation in colorectal cancer (CRC).
|
31278361 |
2020 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apart from SEPT9, other methylated biomarkers including tachykinin-1 (TAC1), somatostatin (SST), and runt-related transcription factor 3 (RUNX3) have been shown to effectively detect CRC in a multitude of sample types.
|
30944663 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of several tumor suppressor gene proteins, runt-related transcription factor 3 (1p36), annexin A10 (4q33), SMAD family member 4 (18q21.1), and deleted in colorectal carcinoma (18q21.3), was evaluated immunohistochemically.
|
22901464 |
2012 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Utilising MethyLight technology, we quantified DNA methylation in MGMT and eight other markers (a CIMP-diagnostic panel; CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1) in 920 population-based colorectal cancers.
|
17339237 |
2007 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results support a role for RUNX3 as a tumour suppressor in colorectal cancer.
|
19223906 |
2009 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All in all, our findings may provide insight into the development of RUNX3 for CRC metastasis diagnostics and therapeutics.
|
27633042 |
2016 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results verified the reliability of using serum RUNX3 and SFRP1 methylation status as a noninvasive biomarker for diagnosis of CRC and that combined detection of RUNX3/SFRP1/CEA panel might be a promising strategy for early detection of CRC.
|
31524773 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RUNX3 copy number predicts the development of UC-associated colorectal cancer.
|
21109941 |
2011 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To study the expression of RUNX3 in colorectal adenocarcinoma tissues and its correlation with microvessel density (MVD), and investigate the clinical pathological prognostic significance of RUNX3 and MVD in patients with colorectal cancer.
|
28107874 |
2017 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Loss of RUNX3 Immunoreactivity in Non-Neoplastic Rectal Mucosa May Predict the Occurrence of Ulcerative Colitis-Associated Colorectal Cancer.
|
30763934 |
2020 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of RUNX3 in bone morphogenetic protein signaling in colorectal cancer.
|
20442291 |
2010 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
These findings suggest that individuals with this SMAD7 variant that develop CRC are more probably to have tumors with greater invasiveness and methylation of RUNX3, which potentially contributes to their poorer observed survival.
|
23104301 |
2013 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RUNX3 aberrant methylation might play an important role in colorectal cancers, especially in poorly-differentiated colorectal cancers.
|
16080503 |
2005 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Our data suggest that RUNX3 inactivation due to promoter hypermethylation in colorectal polyps represents an early event in colorectal cancer (CRC) progression.
|
19174785 |
2009 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We examined RUNX3 expression and the frequency of RUNX3 promoter hypermethylation in 17 colon cancer cell lines and 91 sporadic colorectal cancers.
|
15386381 |
2004 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The aim of the present study was to examine the presence of DNA sequences of five human DNA viruses (assessed by PCR): JC polyoma virus (JCV), human adenovirus (AdV), Epstein-Barr virus (EBV), Kaposi sarcoma-associated herpesvirus (KSHV/HHV8) and human papillomavirus (HPV) in a cohort of 186 sporadic colorectal cancers (CRCs) and related these data with the methylation status of six CpG island methylator phenotype (CIMP)-specific genes (MLH1, CACNA1G, NEUROG1, IGF2, SOCS1, RUNX3) and seven cancer-related genes markers (p16, MINT1, MINT2, MINT31, EN1, SCTR and INHBB) assessed by methylation-specific PCR in 186 and 134 CRC cases, respectively.
|
21625944 |
2011 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
However, no study to date has examined interrelationship between TGFBR2 mutation, RUNX3 methylation, and CIMP in colorectal cancer.
|
17270239 |
2007 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In addition, hypermethylation of RUNX3 was detected in 70 out of 105 colorectal carcinomas (66.7%).
|
24403453 |
2014 |